Related Experiment Videos
Efficacy of fluconazole in cryptococcal meningitis
P D Jones1, D Marriott, B R Speed
1Department of Infectious Diseases, Prince Henry Hospital, Matraville, N.S.W., Australia.
Abstract:
In this clinical trial, oral fluconazole was used to treat cryptococcal meningitis in 32 patients with Acquired Immune Deficiency Syndrome (AIDS). In 11 patients who received 200 to 400 mg/day of fluconazole as primary therapy, a favorable clinical response was obtained in 67% of all evaluable patients. A negative cerebrospinal fluid (CSF) culture was also reported for 86% of these cases. Fluconazole was used as second-line therapy in an additional 15 patients who were not responsive to therapy with amphotericin B or amphotericin B combined with flucytosine. Positive clinical and mycologic responses were then obtained in more than 60% of these cases. Following successful treatment with fluconazole as either the primary or secondary antifungal agent, 26 patients were evaluated during maintenance therapy with 100 to 200 mg daily of fluconazole to prevent recurrence of disease. The relapse rate was 3.2 cases of cryptococcal meningitis per 1000 patient weeks, with a mean duration of 22 weeks for maintenance therapy. An additional six patients who were also treated with either amphotericin B alone or in combination with flucytosine but were asymptomatic or CSF culture negative when treatment with fluconazole was initiated were evaluated for the safety and efficacy of maintenance therapy. Thus, treatment of fluconazole appears to be efficacious as well as safe. The incidence of superimposed infections associated in these AIDS patients make it difficult to accurately assess any adverse effects.
Insights
Oral fluconazole effectively treated cryptococcal meningitis in patients with Acquired Immune Deficiency Syndrome (AIDS). This antifungal medication demonstrated favorable clinical and mycological responses, with a low relapse rate during maintenance therapy.
Area of Science:
- Infectious Diseases
- Mycology
- Clinical Pharmacology
Background:
- Cryptococcal meningitis is a serious opportunistic infection in patients with Acquired Immune Deficiency Syndrome (AIDS).
- Traditional treatments like amphotericin B have limitations, necessitating exploration of alternative antifungal agents.
Purpose of the Study:
- To evaluate the efficacy and safety of oral fluconazole for treating cryptococcal meningitis in AIDS patients.
- To assess fluconazole's role as both primary and secondary therapy.
- To determine the effectiveness of fluconazole maintenance therapy in preventing disease recurrence.
Main Methods:
- A clinical trial involving 32 patients with AIDS and cryptococcal meningitis.
- Fluconazole administered as primary therapy (200-400 mg/day) or second-line therapy after amphotericin B.
- Maintenance therapy (100-200 mg/day) evaluated for relapse prevention.
Main Results:
- Primary therapy with fluconazole achieved favorable clinical response in 67% and negative CSF cultures in 86% of evaluable patients.
- Second-line therapy showed positive clinical and mycological responses in over 60% of patients.
- Maintenance therapy demonstrated a low relapse rate of 3.2 cases per 1000 patient-weeks.
Conclusions:
- Oral fluconazole is an efficacious and safe treatment option for cryptococcal meningitis in AIDS patients.
- Fluconazole offers a viable alternative for both initial treatment and salvage therapy.
- Low relapse rates suggest effectiveness in long-term management and prevention of recurrence.